Related Experiment Video
Updated: Aug 4, 2026
Comprehensive & Cost Effective Laboratory Monitoring of HIV/AIDS: an African Role Model
Published on: October 31, 2010
Defining a Central Monitoring Capability: Sharing the Experience of TransCelerate BioPharma's Approach, Part 2
Jacqueline Gough1, Brett Wilson2, Mireille Zerola3
11 Clinical Risk Management, Eli Lilly and Company, Indianapolis, IN, USA.
Background:
TransCelerate's model approach to risk-based monitoring (RBM) includes the application of the appropriate monitoring activities to enable both the early detection and timely resolution of issues. This article is a follow-up to part 1, published in the September 2014 issue with the same title.
Methods:
The intent of this paper is to share information on what has been learned by various companies' applications of central monitoring activities based on different RBM operating models. A library of risk indicators has been created, and this paper provides additional guidance on what has been learned in the application of these tools.
Results:
The goal is to share the needs related to people, process, and technology as experienced by TransCelerate member companies.
Conclusions:
One of the primary issue detection methods of central monitoring is the proactive identification of areas of focus through the use of risk indicators.
